SCHEMBL6472011

SCHEMBL6472011

Cc1ccc(N=C=O)cc1OC(C)C

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.54
TRPA1 O75762 1/20 0.54
TDP1 Q9NUW8 3/20 0.41
MAPK1 P28482 1/20 0.41
TSHR P16473 1/20 0.35
MAPT P10636 2/20 0.33
ALDH1A3 P47895 1/20 0.33
NPY1R P25929 1/20 0.33
NPY2R P49146 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33
ERN1 O75460 1/20 0.31
FFAR4 Q5NUL3 1/20 0.31
CYP1A2 P05177 2/20 0.30
IRAK4 Q9NWZ3 2/20 0.30
CYP2C9 P11712 1/20 0.30
CYP2C19 P33261 1/20 0.30
SCN5A Q14524 1/20 0.30
SCN2A Q99250 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9697465 0.83 P2RY6 (0.35) CYP3A4TRPA1TDP1MAPTALDH1A3
SCHEMBL9533540 0.82 TDP1 (0.56) CYP3A4TRPA1TDP1MAPK1TSHR
SCHEMBL10440379 0.81 TRPA1 (0.45) CYP3A4TRPA1TDP1MAPK1TSHR
SCHEMBL12458569 0.80 CYP3A4 (0.54) CYP3A4TRPA1TDP1MAPK1TSHR
SCHEMBL11804851 0.79 MAPK1 (0.56) CYP3A4TRPA1TDP1MAPK1
SCHEMBL9776985 0.78 CYP3A4 (0.38) CYP3A4TRPA1TDP1MAPK1TSHR
SCHEMBL17593306 0.76 CYP3A4 (0.39) CYP3A4TRPA1TDP1MAPK1TSHR
SCHEMBL19461641 0.75 RXRA (0.46) CYP3A4TRPA1TDP1MAPK1
SCHEMBL9111062 0.74 ALDH1A3 (0.53) CYP3A4TRPA1TDP1MAPK1TSHR
SCHEMBL10316838 0.74 MAPK1 (0.46) CYP3A4TRPA1TDP1MAPK1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6962926-B2 Antagonist of MCP-1 function, and compositions and methods of use thereof TELIK, INC. (US) 2005-11-08 US disclosed
WO-2005014600-A1 ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF TELIK, INC. (US) 2005-02-17 WO disclosed
US-20040198719-A1 Antagonist of MCP-1 function, and compositions and methods of use thereof SANWA KAGAKU KENKYUSHO CO., LTD. (JP) 2004-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040198719-A1 Antagonist of MCP-1 function, and compositions and methods of use thereof CCR1, CCL11, CCL2 CYP3A4 3230/4885TRPA1 203/4885TDP1 4043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.